Tagitanlimab (HBM-9167) 是一种人源化抗 PD-L1 抗体(IgG1κ 型)。Tagitanlimab 可选择性地阻断PD-L1和PD-1的相互作用。Tagitanlimab 具有研究复发性或转移性鼻咽癌 (NPC) 的潜力。
| 生物活性 | Tagitanlimab (HBM-9167) is ahumanized anti-PD-L1 antibody(IgG1κ type). Tagitanlimab selectively blocks the interaction ofPD-L1andPD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC)[1][2]. |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com